CWAN Price Prediction Next Week
Prediction and Recommendation for CWAN Stock
Based on the analysis of news sentiment, technical indicators, and insider activity, here is the prediction and recommendation for CWAN stock:
News Sentiment Analysis:
- Insider Activity: Significant insider selling activity, with the CFO selling 5,000 shares recently. This indicates negative sentiment among insiders.
- Acquisition News: The acquisition of Enfusion is progressing, with regulatory approval received. This could provide long-term growth but may not immediately impact the stock price.
- Analyst Ratings: Analysts maintain a Moderate Buy rating with a price target of $32.20, indicating potential upside.
Technical Indicators:
- RSI (14): 47.13, indicating neutral momentum.
- MACD: Slightly bullish with a positive signal line crossover.
- Fibonacci Levels: Resistance at $31.28 and support at $27.55.
- SMA (20): $29.20, indicating the stock is trading near its short-term average.
Price Prediction:
The stock is expected to trade between $27.55 and $28.50 next week. If the stock breaks below $27.55, it may trend downward.
Recommendation:
Sell CWAN stock at the current price of $27.61, as the stock is near its support level and insider sentiment is bearish. Consider using put options if the price breaks below $27.55.
CWAN Similar Chart Price Prediction
The price of CWAN is predicted to go up -1.25%, based on the high correlation periods with ENFN. The similarity of these two price pattern on the periods is 96.88%.
CWAN
ENFN
Down: -1.25%Similarity: 96.88%
CWAN Revenue Forecast
CWAN EPS Forecast
CWAN FAQs
What is CWAN revenue forecast for next quarter？
What is CWAN eps forecast for next quarter？
CWAN Analyst's Forecast
Rishi Jaluria
RBC Capital
Buy
2025-02-20
Price Target
$30 → $36
Upside
+20.24%
RBC Capital raised the firm's price target on Clearwater Analytics to $36 from $30 and keeps an Outperform rating on the shares. The company reported strong Q4 results, marked by 25% annual recurring revenue growth and net retention reaching 116%, and while the quarter benefited from some nonrecurring business, excluding this, revenue would have still been well ahead of consensus, the analyst tells investors in a research note.
Arvind Ramnani
Piper Sandler
Hold → Buy
2025-02-20
Price Target
$28 → $36
Upside
+20.24%
James Faucette
Morgan Stanley
Hold → Buy
2025-01-17
Price Target
$30 → $34
Upside
+21.52%
